The short answer
Confirm the valerian species before combining this root product with cyclobenzaprine. If it is Valeriana officinalis, added drowsiness is a reasonable concern, but the generic root name does not establish that identity.
What this answer covers
Generic root/rhizome identity; confirm Valeriana officinalis before applying species-specific guidance.
- Supplement or preparation
- Radix et Rhizoma Valerianae
- Medication ingredient
- cyclobenzaprine
The alertness effects may overlap
Cyclobenzaprine labeling cautions that other CNS depressants can intensify its effects. Supplement guidance advises against combining this herb with sedating substances, supporting a conditional precaution.
A sleep-benefit result is not a safety result
A kava and valerian trial did not establish sleep or anxiety benefit. It did not test cyclobenzaprine, and the lack of benefit cannot establish absence of impairment.
Identify both products
The generic root/rhizome name does not establish a valerian species. Cyclobenzaprine swallowed and sublingual formulations differ, and evidence does not define a safe supplement dose across them.
Have co-use reviewed
Ask the prescriber before adding the herb and avoid driving while impaired. A short timing gap has not been shown to prevent additive effects. Seek urgent help for severe confusion, breathing difficulty or inability to wake.
Evidence and practical considerations
Side effects & toxicity
The current generic root/rhizome identity does not establish Valeriana officinalis. Species-specific sedation evidence cannot validate the original unidentified-product claim; a narrower confirmed-species precaution is retained separately.
- Exact scope
- Generic root/rhizome identity; confirm Valeriana officinalis before applying species-specific guidance. with Cyclobenzaprine21949 IN; hydrochloride swallowed IR/ER and sublingual products with formulation-specific indications.
- Medication form and route
- oral medication; sublingual medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cyclobenzaprine
CNS-depressant and serotonin-syndrome warnings; concomitant MAOIs and14days after stopping contraindicated.
How this applies: Exact cyclobenzaprine RxCUI 21949 IN, with stated salt/formulation/route bridge.
Not extended-release or sublingual dosing; supplement-specific risk unmeasured.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cyclobenzaprine
CNS-depressant and serotonergic precautions; MAOI contraindication.
How this applies: Exact cyclobenzaprine RxCUI 21949 IN, with stated salt/formulation/route bridge.
Different release/directions from immediate-release and sublingual products.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cyclobenzaprine
CNS depression and serotonergic precautions; MAOI contraindication retained.
How this applies: Exact cyclobenzaprine RxCUI 21949 IN, with stated salt/formulation/route bridge.
Not swallowed-tablet dosing; sublingual product administration instructions are not a universal supplement-separation rule.
Source 4: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Possible but unproven sleep-inducing effects; advises against combining valerian with alcohol or sedatives.
How this applies: Original source interpreted for cyclobenzaprine only within the stated preparation and endpoint limits.
Not a direct cyclobenzaprine combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 5: federal botanical identity and safety guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of Valeriana officinalis.
The fact sheet covers only V. officinalis among more than 250 valerian species; possible additive sedation is theoretical.
How this applies: Original source interpreted for cyclobenzaprine only within the stated preparation and endpoint limits.
Not a direct cyclobenzaprine combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 6: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 participants with anxiety and insomnia.
Neither botanical improved its primary anxiety/insomnia outcome over placebo.
How this applies: Original source interpreted for cyclobenzaprine only within the stated preparation and endpoint limits.
Not a direct cyclobenzaprine combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Research assessment: · Open full citations ↗
Side effects & toxicity
If the product is confirmed as Valeriana officinalis, additive drowsiness with cyclobenzaprine is a conditional concern based on medication labeling and species-specific guidance.
- Exact scope
- Confirmed Valeriana officinalis root preparation, not an unidentified generic valerian root. with Exact cyclobenzaprine ingredient and labeled formulations described in this article.
- Medication form and route
- oral medication; sublingual medication; oral supplement
What remains uncertain
- No exact-pair event rate or protective interval established.
Factors that may matter: Confirmed botanical identity; Preparation; Dose; Other sedatives.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cyclobenzaprine
CNS-depressant and serotonin-syndrome warnings; concomitant MAOIs and14days after stopping contraindicated.
How this applies: Exact cyclobenzaprine RxCUI 21949 IN, with stated salt/formulation/route bridge.
Not extended-release or sublingual dosing; supplement-specific risk unmeasured.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cyclobenzaprine
CNS-depressant and serotonergic precautions; MAOI contraindication.
How this applies: Exact cyclobenzaprine RxCUI 21949 IN, with stated salt/formulation/route bridge.
Different release/directions from immediate-release and sublingual products.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cyclobenzaprine
CNS depression and serotonergic precautions; MAOI contraindication retained.
How this applies: Exact cyclobenzaprine RxCUI 21949 IN, with stated salt/formulation/route bridge.
Not swallowed-tablet dosing; sublingual product administration instructions are not a universal supplement-separation rule.
Source 4: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Possible but unproven sleep-inducing effects; advises against combining valerian with alcohol or sedatives.
How this applies: Original source interpreted for cyclobenzaprine only within the stated preparation and endpoint limits.
Not a direct cyclobenzaprine combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 5: federal botanical identity and safety guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of Valeriana officinalis.
The fact sheet covers only V. officinalis among more than 250 valerian species; possible additive sedation is theoretical.
How this applies: Original source interpreted for cyclobenzaprine only within the stated preparation and endpoint limits.
Not a direct cyclobenzaprine combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 6: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 participants with anxiety and insomnia.
Neither botanical improved its primary anxiety/insomnia outcome over placebo.
How this applies: Original source interpreted for cyclobenzaprine only within the stated preparation and endpoint limits.
Not a direct cyclobenzaprine combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact cyclobenzaprine article with formulation-specific evidence and uncertainty. | |
| Research summary published |
Article revision: 910101ecd72f6ddf
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.